310 related articles for article (PubMed ID: 30297804)
1. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
2. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
3. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation.
Wang X; Yue P; Chan CB; Ye K; Ueda T; Watanabe-Fukunaga R; Fukunaga R; Fu H; Khuri FR; Sun SY
Mol Cell Biol; 2007 Nov; 27(21):7405-13. PubMed ID: 17724079
[TBL] [Abstract][Full Text] [Related]
5. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.
Grzmil M; Morin P; Lino MM; Merlo A; Frank S; Wang Y; Moncayo G; Hemmings BA
Cancer Res; 2011 Mar; 71(6):2392-402. PubMed ID: 21406405
[TBL] [Abstract][Full Text] [Related]
6. MNK1 pathway activity maintains protein synthesis in rapalog-treated gliomas.
Grzmil M; Huber RM; Hess D; Frank S; Hynx D; Moncayo G; Klein D; Merlo A; Hemmings BA
J Clin Invest; 2014 Feb; 124(2):742-54. PubMed ID: 24401275
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell lymphoma (CTCL) cells.
Marzec M; Liu X; Wysocka M; Rook AH; Odum N; Wasik MA
PLoS One; 2011; 6(9):e24849. PubMed ID: 21949767
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
[TBL] [Abstract][Full Text] [Related]
9. The MNK-1/eIF4E pathway as a new therapeutic pathway to target inflammation and remodelling in asthma.
Seidel P; Sun Q; Costa L; Lardinois D; Tamm M; Roth M
Cell Signal; 2016 Oct; 28(10):1555-62. PubMed ID: 27418099
[TBL] [Abstract][Full Text] [Related]
10. Exosome-mediated miR-7-5p delivery enhances the anticancer effect of Everolimus via blocking MNK/eIF4E axis in non-small cell lung cancer.
Liu S; Wang W; Ning Y; Zheng H; Zhan Y; Wang H; Yang Y; Luo J; Wen Q; Zang H; Peng J; Ma J; Fan S
Cell Death Dis; 2022 Feb; 13(2):129. PubMed ID: 35136028
[TBL] [Abstract][Full Text] [Related]
11. Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001.
Kuo SH; Hsu CH; Chen LT; Lu YS; Lin CH; Yeh PY; Jeng HJ; Gao M; Yeh KH; Cheng AL
Eur J Cancer; 2011 May; 47(8):1244-57. PubMed ID: 21334199
[TBL] [Abstract][Full Text] [Related]
12. Mnk1 is required for angiotensin II-induced protein synthesis in vascular smooth muscle cells.
Ishida M; Ishida T; Nakashima H; Miho N; Miyagawa K; Chayama K; Oshima T; Kambe M; Yoshizumi M
Circ Res; 2003 Dec; 93(12):1218-24. PubMed ID: 14605021
[TBL] [Abstract][Full Text] [Related]
13. The antileukemia roles of PP242 alone or in combination with daunorubicin in acute leukemia.
Shi F; Yang X; Gong Y; Shi R; Yang X; Naren D; Wu J
Anticancer Drugs; 2015 Apr; 26(4):410-21. PubMed ID: 25535978
[TBL] [Abstract][Full Text] [Related]
14. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
15. Mnk mediates integrin α6β4-dependent eIF4E phosphorylation and translation of VEGF mRNA.
Korneeva NL; Soung YH; Kim HI; Giordano A; Rhoads RE; Gram H; Chung J
Mol Cancer Res; 2010 Dec; 8(12):1571-8. PubMed ID: 21047768
[TBL] [Abstract][Full Text] [Related]
16. Shiga toxins activate translational regulation pathways in intestinal epithelial cells.
Colpoys WE; Cochran BH; Carducci TM; Thorpe CM
Cell Signal; 2005 Jul; 17(7):891-9. PubMed ID: 15763431
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches.
Martínez A; Sesé M; Losa JH; Robichaud N; Sonenberg N; Aasen T; Ramón Y Cajal S
PLoS One; 2015; 10(4):e0123352. PubMed ID: 25923732
[TBL] [Abstract][Full Text] [Related]
18. Eukaryotic initiation factor 4E is a novel effector of mTORC1 signaling pathway in cross talk with Mnk1.
Batool A; Majeed ST; Aashaq S; Majeed R; Bhat NN; Andrabi KI
Mol Cell Biochem; 2020 Feb; 465(1-2):13-26. PubMed ID: 31782083
[TBL] [Abstract][Full Text] [Related]
19. Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2).
Rolfe M; McLeod LE; Pratt PF; Proud CG
Biochem J; 2005 Jun; 388(Pt 3):973-84. PubMed ID: 15757502
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases.
Konicek BW; Stephens JR; McNulty AM; Robichaud N; Peery RB; Dumstorf CA; Dowless MS; Iversen PW; Parsons S; Ellis KE; McCann DJ; Pelletier J; Furic L; Yingling JM; Stancato LF; Sonenberg N; Graff JR
Cancer Res; 2011 Mar; 71(5):1849-57. PubMed ID: 21233335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]